Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21248665 | 0.83 | CA2 (0.35) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL10523675 | 0.79 | CA2 (0.60) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL28154136 | 0.79 | CA2 (0.40) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL14877302 | 0.70 | GABRA1 (0.60) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL22686107 | 0.70 | CA2 (0.44) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL2280822 | 0.69 | GABRA1 (0.43) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL438553 | 0.69 | CA2 (0.55) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL27965170 | 0.69 | CA2 (0.39) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL2050307 | 0.68 | CA2 (0.48) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL4411468 | 0.68 | KIF11 (0.48) | CA2GABRA1GABRB2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749674-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-12-16 | — | — | EP | claimed |
| US-20200369697-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-11-26 | — | — | US | claimed |
| WO-2019157376-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-08-15 | — | — | WO | claimed |
| EP-3749674-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200369697-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-11-26 | — | — | US | disclosed |
| WO-2019157376-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369697-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MSRB3, MMAB, CYB5R3 | CA2 1952/4885GABRA1 2670/4885GABRB2 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.